Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IMP004
MIFTS: 49

Impetigo

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Impetigo

About this section

MalaCards integrated aliases for Impetigo:

Name: Impetigo 12 74 42 43 15 62 17 71 32

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8504
ICD9CM 34 684
MeSH 43 D007169
NCIt 49 C99088
SNOMED-CT 67 48277006
ICD10 32 L01 L01.0
UMLS 71 C0021099
Sources

Summaries for Impetigo

About this section
MedlinePlus : 42 Impetigo is a skin infection caused by bacteria. It is usually caused by staphylococcal (staph) bacteria, but it can also be caused by streptococcal (strep) bacteria. It is most common in children between the ages of two and six. It usually starts when bacteria get into a break in the skin, such as a cut, scratch, or insect bite. Symptoms start with red or pimple-like sores surrounded by red skin. These sores can be anywhere, but usually they occur on your face, arms and legs. The sores fill with pus, then break open after a few days and form a thick crust. They are often itchy, but scratching them can spread the sores. Impetigo can spread by contact with sores or nasal discharge from an infected person. You can treat impetigo with antibiotics.

MalaCards based summary : Impetigo is related to impetigo herpetiformis and bullous impetigo, and has symptoms including fever, pruritus and exanthema. An important gene associated with Impetigo is DSG1 (Desmoglein 1), and among its related pathways/superpathways are Defensins and Keratinization. The drugs Mupirocin and Retapamulin have been mentioned in the context of this disorder. Affiliated tissues include skin, colon and liver, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A pyoderma consisting of three forms of skin lesions having either a thick, adherent, recurrent, dirty yellow crust with an erythematous margin (common or superficial impetigo) or lessions which are superficial, thin-walled, and bullous as found in bullous impetigo. The lesions in bullous (staphylococcal) impetigo, which are always caused by S aureus, are superficial, thin-walled, and bullous.

PubMed Health : 62 About impetigo: Impetigo is an itchy and sometimes painful infection of the outer layers of skin that is especially common in young children. It is caused by bacteria and is highly contagious. For that reason, children who have impetigo are not allowed to return to school or day care until they are no longer contagious – about 24 hours after the start of treatment with antibiotics. Without treatment, it can remain contagious for several weeks.

Wikipedia : 74 Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is... more...

Sources

Related Diseases for Impetigo

About this section

Diseases related to Impetigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 34.2 SERPINB1 PRTN3 PI3 IL36RN ELANE
2 bullous impetigo 34.0 IL6 EDNRB EDNRA DSG3 DSG1 CALCA
3 pustular psoriasis 33.0 PI3 IL36RN ELANE
4 ecthyma 31.0 MYOM2 DSG1
5 pemphigus foliaceus 30.9 DSG3 DSG2 DSG1
6 exanthem 30.8 PRTN3 IL6 CCR6
7 streptococcal toxic-shock syndrome 30.7 MYOM2 IL6
8 erysipelas 30.5 PI3 MYOM2 IL6 ELANE CALCA
9 pemphigus vegetans 30.5 DSG1 DSC3
10 syphilis 30.3 PRTN3 IL6 CCR6
11 bacterial infectious disease 30.2 PI3 IL6 ELANE CCR6 CAMP
12 psoriasis 30.2 SERPINB1 PI3 IL6 IL36RN ELANE CCR6
13 pyoderma 30.1 MYOM2 IL36RN EDNRB DSG3 DSG1 CCR6
14 pyomyositis 30.1 TST MYOM2 EDNRB
15 rosacea 30.0 IL6 CCR6 CAMP
16 scarlet fever 30.0 TST MYOM2 EDNRB EDNRA
17 toxic shock syndrome 30.0 MYOM2 IL6 EDNRA CAMP
18 iga pemphigus 29.8 DSG3 DSG1 DSC3 DSC1
19 osteomyelitis 29.8 PPP3CA IL6 CALCA
20 pemphigus 29.7 IL6 DSG4 DSG3 DSG2 DSG1 DSC3
21 cellulitis 29.0 IL6 DSG4 DSG3 DSG1 DSC3 DSC1
22 ritter's disease 28.9 TST EDNRB EDNRA DSG4 DSG3 DSG2
23 pemphigus vulgaris, familial 28.6 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
24 skin disease 28.3 PI3 IL6 IL36RN DSG4 DSG3 DSG2
25 prolidase deficiency 11.2
26 acute proliferative glomerulonephritis 11.2
27 recessive dystrophic epidermolysis bullosa-generalized other 11.2
28 pustulosis of palm and sole 10.6
29 dermatitis 10.6
30 scabies 10.6
31 herpetiform pemphigus 10.6 DSG3 DSG1
32 tinea imbricata 10.5 DSG3 DSG1
33 glomerulonephritis 10.5
34 indolent myeloma 10.4 MYOM2 IL6
35 engraftment syndrome 10.4 PI3 CALCA
36 dermatitis, atopic 10.4
37 pulmonary arterial hypertension associated with connective tissue disease 10.4 EDNRB EDNRA
38 glomeruloid hemangioma 10.4 MYOM2 IL6
39 pharyngitis 10.4
40 pulmonary hemosiderosis 10.4 PRTN3 IL36RN
41 gorham's disease 10.4 IL6 CALCA
42 acute diffuse nephritis 10.4 MYOM2 DSG1
43 dermatophytosis 10.4
44 castleman disease 10.4 IL6 DSG3 DSG1
45 lichen planus 10.4 IL6 DSG3 DSG1
46 bronchopneumonia 10.4 PI3 IL6 ELANE
47 psoriasis 14, pustular 10.4
48 hypoparathyroidism 10.4
49 radiation proctitis 10.3 EDNRB EDNRA
50 scleral disease 10.3 PRTN3 IL6 CCR6

Comorbidity relations with Impetigo via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Impetigo:



Diseases related to Impetigo
Sources

Symptoms & Phenotypes for Impetigo

About this section

UMLS symptoms related to Impetigo:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Impetigo:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CAMP CCR6 DSG3 DSG4 EDNRA EDNRB
2 immune system MP:0005387 10 CAMP CCR6 DSC1 DSG2 DSG3 DSG4
3 integument MP:0010771 9.7 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
4 vision/eye MP:0005391 9.28 CAMP DSC1 DSC3 DSG1 DSG3 EDNRA
Sources

Drugs & Therapeutics for Impetigo

About this section

PubMed Health treatment related to Impetigo: 62

As long as impetigo doesn't spread beyond a small patch of skin , disinfectant solutions or creams are often recommended. But it isn't clear whether they work. Antibiotic creams have proven effective. Antibiotics that are swallowed (oral antibiotics ) are usually only prescribed if a child has impetigo on a large area of skin or if several parts of their body are affected. Antibiotic tablets are more likely to have side effects than antibiotic creams. For instance, they may cause gastrointestinal (stomach and bowel ) problems. Good hygiene is the key to avoiding infection , especially washing hands frequently, not sharing towels, and washing worn clothing at 60°C (140°F) or higher. It's a good idea to keep the child’s fingernails trimmed very short so they can't scratch themselves as much.

Drugs for Impetigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
2
Retapamulin Approved Phase 4 224452-66-8 6918462
3
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
4
Azithromycin Approved Phase 4 83905-01-5 447043 55185
5
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
6
Petrolatum Approved, Investigational Phase 4 8009-03-8
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
9
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
10 Antiparasitic Agents Phase 4
11 Dermatologic Agents Phase 4
12 Immunologic Factors Phase 4
13 Vasoconstrictor Agents Phase 4
14 Emollients Phase 4
15 Immunosuppressive Agents Phase 4
16 Calcineurin Inhibitors Phase 4
17 Anti-Bacterial Agents Phase 4
18 Anti-Infective Agents Phase 4
19
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
20
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
21
Zinc Approved, Investigational Phase 3 7440-66-6 32051
22
Malathion Approved, Investigational Phase 3 121-75-5 4004
23 Respiratory System Agents Phase 2, Phase 3
24 Expectorants Phase 2, Phase 3
25 Terpin Phase 2, Phase 3
26 Antibiotics, Antitubercular Phase 3
27 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
28 methicillin Phase 3
29 Cholinergic Agents Phase 3
30 Cholinesterase Inhibitors Phase 3
31 Neurotransmitter Agents Phase 3
32
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
33 Vaccines Phase 2
34 Antibodies Phase 2
35 Immunoglobulins, Intravenous Phase 2
36 Rho(D) Immune Globulin Phase 2
37 gamma-Globulins Phase 2
38 Immunoglobulins Phase 2
39 Papaya Approved Phase 1
40
Diethylcarbamazine Approved, Investigational, Vet_approved 90-89-1 3052
41
Albendazole Approved, Vet_approved 54965-21-8 2082
42
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
43
Vitamin D3 Approved, Nutraceutical 67-97-0 5280795 6221
44 Liver Extracts
45 Trace Elements
46 Micronutrients
47 Vitamins
48 Hormones
49 Nutrients
50 Calcium, Dietary

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
2 Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Completed NCT01126268 Phase 4 Retapamulin (Altabax)
3 Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology Completed NCT02775617 Phase 4 Ivermectin;Azithromycin;Permethrin
4 A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba Completed NCT01388517 Phase 4 Tacrolimus;Calcitriol;Petrolatum
5 Retapamulin for Reducing MRSA Nasal Carriage Completed NCT01461668 Phase 4 Retapamulin;Placebo
6 A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients Terminated NCT00986856 Phase 4 Fucidin® cream
7 A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo. Unknown status NCT01611909 Phase 2, Phase 3 p-menthane-3,8-diol oil
8 A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT02090764 Phase 3 Ozenoxacin;Placebo
9 A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo. Completed NCT00133848 Phase 3 SB-275833 ointment, 1%
10 Ph-III Randomized, Multicentric, Controlled , Non-inferiority Trial to Evaluate the Safety and Efficacy of Mupirocin Gel 20 mg/g Versus Mupirocin Ointment 20 mg/g and Placebo in the Treatment of Impetigo in Paediatric Population Completed NCT04287777 Phase 3 Mupirocin gel;Mupirocin ointment;Placebo
11 A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo Completed NCT01397461 Phase 3 ozenoxacin placebo;retapamulin 1% ointment;ozenoxacin 1% cream
12 An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo Completed NCT00133874 Phase 3 SB-275833 ointment, 1%
13 A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo Completed NCT01670032 Phase 2, Phase 3 Experimental: CD07223 1.5 % Topical Gel BID;Experimental: CD07223 1.5% Topical Gel TID;Placebo Comparator: CD07223 vehicle gel BID;Placebo Comparator: CD07223 vehicle gel TID
14 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00852540 Phase 3 Retpamulin Ointment, 1%;Linezolid
15 Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness. Completed NCT00408356 Phase 3 Zinc
16 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands Completed NCT03236168 Phase 3 Ivermectin;Permethrin 5%;Malathion Shampoo 0.5%
17 Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo Completed NCT03429595 Phase 2 ATx201
18 The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo Completed NCT00758862 Phase 2 2% TD1414 Cream
19 A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo Completed NCT01171326 Phase 2 Topical Minocycline Foam FXFM244
20 Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) Completed NCT00626795 Phase 2 TD1414 2% cream;TD1414 2% cream;Bactroban® (mupirocin) 2% cream
21 A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo Completed NCT01803035 Phase 2 LTX-109 1 %;LTX-109 2 %;Placebo gel
22 A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo Completed NCT01367314 Phase 2 NVC-422
23 A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection Completed NCT01223222 Phase 2 LTX-109
24 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
25 The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT01943136 Phase 1 papaya 1% extract ointment;mupirocin 2% ointment
26 Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union Completed NCT01153828 Retapamulin;Co-prescription of retapamulin and topical mupirocin;Co-prescription of retapamulin and topical fusidic acid
27 Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study) Completed NCT02902822
28 An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information Completed NCT01445600 ALTARGO(retapamulin)
29 East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities Completed NCT00884728
30 Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections Completed NCT02010294
31 Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States Completed NCT01153880 Retapamulin;Co-prescription of retapamulin and topical mupirocin
32 Epidemiological Surveillance in India of Group A Streptococcal Infections Including Pharyngitis and Impetigo Supported by Indo-US Vaccine Action Program Completed NCT00342199
33 A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis Completed NCT01714245
34 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
35 Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH) Completed NCT00800449
36 Pilot Study To Determine The Underlying Mechanisms For Infection And Colonization By Staphylococcus Aureus Of The Skin Of Atopic Dermatitis Subjects With And Without A History Of Eczema Herpeticum (ADVN MRSA 10) Completed NCT00822276
37 "Clinical and Epidemiological Characteristics of Inflammatory Rhinitis in Patients on Biotherapies" Recruiting NCT04132258
38 Effectiveness of Vitamin D Supplementation to Reduce Injury and Illness in the UK Armed Forces With Specific Reference to Stress Fracture Risk Reduction Recruiting NCT03963128
39 Hypo-pigmented Skin Lesions in Children : Dermoscopic Evaluation Not yet recruiting NCT04089475

Search NIH Clinical Center for Impetigo

Cochrane evidence based reviews: impetigo

Sources

Genetic Tests for Impetigo

About this section
Sources

Anatomical Context for Impetigo

About this section

MalaCards organs/tissues related to Impetigo:

40
Skin, Colon, Liver, Monocytes, T Cells, Neutrophil, Breast
Sources

Publications for Impetigo

About this section

Articles related to Impetigo:

(show top 50) (show all 1495)
# Title Authors PMID Year
1
Formaldehyde as an alternative to antibiotics for treatment of refractory impetigo and other infectious skin diseases. 61 42
31393185 2019
2
Impetigo herpetiformis responsive to secukinumab. 61 42
31361940 2019
3
Prevalence of scabies and impetigo in the Solomon Islands: a school survey. 42 61
31519153 2019
4
Topical antibiotics in the dermatological clinical practice: indications, efficacy and adverse effects. 61
32531105 2020
5
Preparation and characterization of a novel thermosensitive and bioadhesive cephalexin nanohydrogel: a promising platform for topical antibacterial delivery. 61
32441175 2020
6
[Genital impetigo]. 61
32229036 2020
7
Ozenoxacin (Xepi) for the Treatment of Impetigo. 61
32538600 2020
8
Trichloroacetic acid peel complicated with impetigo contagious infection. 61
32323453 2020
9
Bullous impetigo masquerading as pemphigus foliaceus in an adult patient. 61
32382637 2020
10
A case of goggle-mask-related impetigo at the time of the COVID-19 pandemic. 61
32436604 2020
11
Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. 61
32406109 2020
12
Kampo medicines suppress the production of exfoliative toxins causing impetigo in Staphylococcus aureus. 61
32415796 2020
13
[Atypical hand-foot-mouth disease virus genotyping in a pediatric hospital in Buenos Aires city, Argentina]. 61
32199065 2020
14
Impetigo/Staphylococcal Scalded Skin Disease. 61
32238552 2020
15
Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin. 61
31131410 2020
16
Longitudinal Analysis of Group A Streptococcus emm Types and emm Clusters in a High-Prevalence Setting: Relationship between Past and Future Infections. 61
31748786 2020
17
Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis. 61
31971270 2020
18
Pediatric dermatology emergencies. 61
32352437 2020
19
Skin infections in Australian Aboriginal children: a narrative review. 61
31630410 2020
20
Association of Atopic Dermatitis With Bacterial, Fungal, Viral, and Sexually Transmitted Skin Infections. 61
32049716 2020
21
A review of the antimicrobial potential of herbal drugs used in popular Italian medicine (1850s-1950s) to treat bacterial skin diseases. 61
31790819 2020
22
Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. 61
32258344 2020
23
Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions. 61
32550690 2020
24
Skin Infections and Outpatient Burn Management: Bacterial Skin Infections. 61
31995349 2020
25
Sleep disturbance and atopic dermatitis: A bidirectional relationship? 61
32097844 2020
26
Osteomyelitis complicating secondarily infected atopic eczema: two case reports and a narrative literature review. 61
32008574 2020
27
Eczema herpeticum: A medical emergency in patients with atopic dermatitis. 61
32226756 2020
28
Disseminated bullous impetigo and atopic dermatitis: Case series and literature review. 61
31755570 2020
29
Staphylococcus aureus Isolated from Skin from Atopic-Dermatitis Patients Produces Staphylococcal Enterotoxin Y, Which Predominantly Induces T-Cell Receptor Vα-Specific Expansion of T Cells. 61
31740530 2020
30
Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents. 61
31958794 2020
31
Bioactivity, Compounds Isolated, Chemical Qualitative, and Quantitative Analysis of Cymbaria daurica Extracts. 61
32116723 2020
32
Prevalence and Associations of General Practice Registrars' Management of Impetigo: A Cross-Sectional Analysis From the Registrar Clinical Encounters in Training (ReCEnT) Study. 61
32363105 2020
33
Prevalence, Clinical Features and Antibiotic Susceptibility of Group A Streptococcal Skin Infections in School Children in Urban Western and Northern Uganda. 61
31568247 2019
34
Data augmentation in dermatology image recognition using machine learning. 61
31140653 2019
35
[Impetigo of the face and trunk]. 61
32237623 2019
36
Wolf's Isotopic Response after Herpes Zoster Infection: A Study of 24 New Cases and Literature Review. 61
31321443 2019
37
Acute rheumatic fever diagnosis and management: Review of the global implications of the new revised diagnostic criteria with a focus on Saudi Arabia. 61
31516307 2019
38
Antibiotic stewardship in skin infections: a cross-sectional analysis of early-career GP's management of impetigo. 61
31662391 2019
39
SToP (See, Treat, Prevent) skin sores and scabies trial: study protocol for a cluster randomised, stepped-wedge trial for skin disease control in remote Western Australia. 61
31551385 2019
40
Talking skin: attitudes and practices around skin infections, treatment options, and their clinical management in a remote region in Western Australia. 61
31540550 2019
41
The diagnosis of scabies by non-expert examiners: A study of diagnostic accuracy. 61
31425513 2019
42
Doctors should treat impetigo with antiseptics not antibiotics, says NICE. 61
31416810 2019
43
[Tinea barbae profunda due to Trichophyton mentagrophytes : Case report and review]. 61
31001659 2019
44
Therapeutic Potential of an Endolysin Derived from Kayvirus S25-3 for Staphylococcal Impetigo. 61
31443379 2019
45
Human Keratinocytes Use Sphingosine 1-Phosphate and its Receptors to Communicate Staphylococcus aureus Invasion and Activate Host Defense. 61
30807768 2019
46
Topical Ozenoxacin Cream 1% for Impetigo: A Review 61
31334625 2019
47
Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. 61
30346521 2019
48
A cluster of acute rheumatic fever cases among Aboriginal Australians in a remote community with high baseline incidence. 61
30994967 2019
49
Staphylococcus aureus versus neutrophil: Scrutiny of ancient combat. 61
31002964 2019
50
Echtyma gangrenosum caused by coinfection with group A Streptococcus and Staphylococcus aureus: an emerging etiology? Case reports and literature review. 61
31210583 2019
Sources

Variations for Impetigo

About this section
Sources

Expression for Impetigo

About this section
Search GEO for disease gene expression data for Impetigo.
Sources

Pathways for Impetigo

About this section

Pathways related to Impetigo according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Defensins 65
Show member pathways
 11.69 PRTN3 PI3 ELANE CCR6 CAMP
2
Keratinization 65
Show member pathways
 11.62 PI3 DSG4 DSG3 DSG2 DSG1 DSC3
3
C-MYB transcription factor network 1
11.32 PRTN3 PPP3CA ELANE
4
Endothelin Pathways 1
10.86 EDNRB EDNRA CALCA
Sources

GO Terms for Impetigo

About this section

Cellular components related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 SERPINB1 PRTN3 PI3 IL6 IL36RN ELANE
2 extracellular space GO:0005615 9.97 TST SERPINB1 PRTN3 PI3 IL6 IL36RN
3 cell GO:0005623 9.91 PPP3CA IL6 ELANE EDNRB EDNRA CCR6
4 cell junction GO:0030054 9.8 PPP3CA DSG4 DSG3 DSG2 DSG1 DSC3
5 cell-cell junction GO:0005911 9.63 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
6 desmosome GO:0030057 9.43 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
7 cornified envelope GO:0001533 9.17 PI3 DSG4 DSG3 DSG2 DSG1 DSC3

Biological processes related to Impetigo according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.93 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
2 neutrophil degranulation GO:0043312 9.85 SERPINB1 PRTN3 ELANE DSG1 DSC1 CAMP
3 cellular response to lipopolysaccharide GO:0071222 9.78 IL6 IL36RN EDNRB CAMP
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 EDNRB EDNRA CCR6 CALCA
5 keratinization GO:0031424 9.73 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
6 calcium-mediated signaling GO:0019722 9.71 PPP3CA EDNRB CCR6
7 regulation of blood pressure GO:0008217 9.69 EDNRB EDNRA CALCA
8 cell-cell adhesion GO:0098609 9.63 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
9 antimicrobial humoral response GO:0019730 9.62 PRTN3 PI3 ELANE CAMP
10 negative regulation of bone resorption GO:0045779 9.56 IL6 CALCA
11 enteric nervous system development GO:0048484 9.55 EDNRB EDNRA
12 leukocyte migration involved in inflammatory response GO:0002523 9.52 ELANE CCR6
13 endothelin receptor signaling pathway GO:0086100 9.49 EDNRB EDNRA
14 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.43 DSG4 DSG3 DSG2 DSG1 DSC3 DSC1
15 negative regulation of chemokine biosynthetic process GO:0045079 9.4 IL6 ELANE
16 cornification GO:0070268 9.17 PI3 DSG4 DSG3 DSG2 DSG1 DSC3

Molecular functions related to Impetigo according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.17 PPP3CA DSG4 DSG3 DSG2 DSG1 DSC3
2 gamma-catenin binding GO:0045295 9.16 DSG1 DSC3
3 endothelin receptor activity GO:0004962 8.96 EDNRB EDNRA
Sources

Sources for Impetigo

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....